The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Latysheva N.V.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

Naprienko M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

Filatova E.G.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

Method of onabotulinumtoxin type A injection in chronic migraine: the PREEMPT protocol in clinical practice

Authors:

Latysheva N.V., Naprienko M.V., Filatova E.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8): 93‑96

DOI: 10.17116/jnevro202112108193

Views: 19194

Downloaded: 1499

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Latysheva NV, Naprienko MV, Filatova EG. Method of onabotulinumtoxin type A injection in chronic migraine: the PREEMPT protocol in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8):93‑96. (In Russ.)
https://doi.org/10.17116/jnevro202112108193

 
МСФ на ЯМ
Close metadata
Recommended articles:
Idiopathic hype­rtrophic pachymeningitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):114-119
A comparative asse­ssment of microbiocenosis of saliva and oropharynx in patients with migraine. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):55-62
Sleep diso­rders in patients with medi­cation-overuse headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):93-98
Cognitive beha­vioral therapy in the treatment of patients with chro­nic migraine and concomitant chro­nic inso­mnia: a prospective, randomized trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):110-117
Features of primary forms of headache in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73
Anxiety diso­rders as como­rbid conditions in neuropsychiatric diseases in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):56-64
Headache chro­nification: analysis of evoked pote­ntials for stimulus. Russian Journal of Pain. 2024;(1):18-26
Impact of bullying on adolescents’ health: asso­ciation with psychosomatic complaints. Russian Journal of Preventive Medi­cine. 2024;(3):52-58
Medi­cation-overuse headache: description of patients and medi­cations used before admi­ssion to specialized center. Russian Journal of Pain. 2024;(2):16-21
Calcitonin gene-related peptide in pathophysiology of migraine. Russian Journal of Pain. 2024;(2):56-67

Chronic migraine (CM), a condition where patients experience over 15 days of headache per month, was identified as a separate disease in the International Classification of Headache Disorders 3-beta version. Onabotulinumtoxin type A was approved for the treatment of CM in 2010 after the completion of the extensive PREEMPT (Phase III Research Evaluating Migraine Prophylaxis Therapy) clinical program. The efficacy of onabotulinumtoxin type A was demonstrated in numerous studies in CM and medication-overuse headache. The paper focuses on the PREEMPT injection paradigm and provides guidance for successful and safe treatment of CM.

Keywords:

migraine
onabotulinumtoxin type A
headache
chronic migraine/

Authors:

Latysheva N.V.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

Naprienko M.V.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

Filatova E.G.

Sechenov First Moscow State Medical University (Sechenov University);
Alexander Vein Headache Clinic

Received:

03.06.2021

Accepted:

15.07.2021

List of references:

  1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808.  https://doi.org/10.1177/0333102413485658
  2. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2018;38:1-211.  https://doi.org/10.1177/0333102417738202
  3. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, Steiner TJ. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014;21(5):758-765.  https://doi.org/10.1111/ene.12380
  4. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432.  https://doi.org/10.1136/jnnp.2009.192492
  5. Senthil C., Gunasekaran N. Clinical profile of patients with chronic headache in a tertiary care hospital. Int J Adv Med. 2016;3(3):721-726.  https://doi.org/10.5455/njppp.2018.8.0832011012018
  6. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.  https://doi.org/10.1186/s10194-018-0846-2
  7. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803.  https://doi.org/10.1177/0333102410364676
  8. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-814.  https://doi.org/10.1177/0333102410364677
  9. Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358-1373. https://doi.org/10.1111/j.1526-4610.2011.01990.x
  10. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921-936.  https://doi.org/10.1111/j.1526-4610.2010.01678.x
  11. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48-56.  https://doi.org/10.1016/j.jns.2013.05.003
  12. Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.  https://doi.org/10.1186/s10194-016-0591-3
  13. Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, Kristoffersen ES, Tassorelli C, Ryliskiene K, Petersen JA. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020;27(7):1102-1116. https://doi.org/10.1111/ene.14268
  14. Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18(9):891-902.  https://doi.org/10.1016/s1474-4422(19)30146-2
  15. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853-869.  https://doi.org/10.1177/0333102414527648
  16. Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: Mechanisms of action. Br J Pharmacol. 2014;171:4177-4192. https://doi.org/10.1111/bph.12763
  17. Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain. 2017;18(1):93.  https://doi.org/10.1186/s10194-017-0802-6
  18. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.  https://doi.org/10.1186/s10194-018-0840-8
  19. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406-18.  https://doi.org/10.1111/j.1526-4610.2010.01766.x
  20. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. Headache. 2017;57(5):766-777.  https://doi.org/10.1111/head.13074
  21. Moore KL, Dalley AF, Agur AMR. Clinically Oriented Anatomy (7th ed.). Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
  22. Standring S. Gray’s Anatomy: The Anatomical Basis of Clinical Practice (40th ed.). Edinburgh: Churchill Livingstone/Elsevier; 2008.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.